With Too Much To Handle, Indian Pharma Companies Face Uphill Task In Their Quest To Clinch New Contracts, Grow Further
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Compulsions for large-scale investments, paucity of medicinal chemistry skills that can be valued from an intellectual property standpoint and pressures of sustaining multiple portfolio-based partnerships for discovering new compounds are seen as some of the biggest challenges faced by the Indian pharmaceutical industry, executives at top Indian companies told the PharmAsia Summit in San Francisco Oct. 27